THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

2019 ◽  
Vol 37 ◽  
pp. 89-90 ◽  
Author(s):  
R. Advani ◽  
N.L. Bartlett ◽  
S.M. Smith ◽  
M. Roschewski ◽  
L. Popplewell ◽  
...  
Keyword(s):  
Indolent Lymphoma ◽  
Interim Phase ◽  
Phase 1B

scholarly journals S867 THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 388 ◽  
Author(s):  
R. Advani ◽  
N. Bartlett ◽  
S. Smith ◽  
M. Roschewski ◽  
L. Popplewell ◽  
...  
Keyword(s):  
Indolent Lymphoma ◽  
Interim Phase ◽  
Phase 1B

scholarly journals Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

2014 ◽  
Vol 32 (6) ◽  
pp. 1213-1225 ◽  
Author(s):  
Ajay K. Gopal ◽  
Stefano R. Tarantolo ◽  
Naresh Bellam ◽  
Damian J. Green ◽  
Melissa Griffin ◽  
...  
Keyword(s):  
Therapeutic Protein ◽  
Indolent Lymphoma ◽  
Phase 1B
Sign in / Sign up

Export Citation Format

Share Document